Potential urinary protein biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients

Journal of Cancer

Volumn 5, Issue 2, 2014, Pages 103-114

  Haj Ahmad, Taha A ^a   Abdalla, Moemen A K ^b   Haj Ahmad, Yousef ^b  

^a BROCK UNIVERSITY   (Canada)

^b Alexandria University Faculty Of Science   (Egypt)

Author keywords

Benign Prostatic Hyperplasia; Biomarkers; Prostate Cancer; Proteins; Urine

Indexed keywords

ALPHA 1 MICROGLOBULIN; ALPHA N ACETYLGLUCOSAMINIDASE; APOLIPOPROTEIN D; BETA DEFENSIN 1; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; CADHERIN; CADHERIN 1; CD14 ANTIGEN; CLUSTERIN; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN HEAVY CHAIN; KININOGEN; MATRILIN 4; MESSENGER RNA; MYRISTIC ACID; PEPSINOGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN D SYNTHASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTHROMBIN; TP53INP2 PROTEIN; ULINASTATIN; UNCLASSIFIED DRUG; VITRONECTIN;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; DEREGULATION; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; HUMAN; LIQUID CHROMATOGRAPHY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEOMICS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINALYSIS; VALIDATION STUDY;

EID: 84893597256     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.6890     Document Type: Article

References (66)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D. Global cancer statistics. Cancer J Clin. 2011; 61: 69-90.
2. [Internet] Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ and Cronin KA. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), Nat Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2009_pops09/
3. Boyle P, Severi G and Giles GG. The epidemiology of prostate cancer. Urology Clin North Am. 2003; 30: 209-217.
4. Yin M, Bastacky S, Chandran U, Becich MJ and Dhir R. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. The J of Urology 2008; 179: 892-895.
5. Dunn JE. Cancer epidemiology in populations of the United States-with emphasis on Hawaii and California-and Japan. Cancer Res. 1975; 35(11 Pt. 2): 3240-3245.
6. Mettlin C, Lee F, Drago J and Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67: 2949-2958.
7. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate- specific antigen in serum as a screening test for prostate cancer. N Engl J Med . 1991; 324: 1156-1161.
8. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL and Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. The J of the American Med Association. 1992; 267(16): 2215-2220.
9. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS and Redwine EE. Prostate- specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909-916
10. Rao AR, Motiwala HG and Karim OM. The discovery of prostate- specific antigen. BJU Int. 2008; 101: 5-10.
11. Woolf SH. The accuracy and effectiveness of routine population screening with mammography, prostate specific antigen, and prenatal ultrasound: a review of published scientific evidence. Int J Technol Assess Health Care 2001; 3: 275-304.
12. Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC and Key CR. Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract. 2002; 3: 19.
13. Oh WK, Hurwitz M, Richie JP, D'Amico AV and Kantoff PW. Neoplasms of the Prostate. In: Kufe DW, et al, editors. Cancer Medicine. Hamilton, Canada: BC Decker Inc. 2003
14. Chou R, Jennifer MC, Tracy D, Christina B, Ian B, Rongwei F, Ken G, Helen CK, Clarence L, Ashley MJ, Bruin R and Kenneth L. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Annals of internal medicine. 2011; 155(11): 762-771.
15. Pisitkun T, Johnstone R and Knepper MA. Discovery of urinary biomarkers. Mol Cell Proteomics 2006; 5: 1760-1771.
16. Truong M, Yang B and Jarrard D. Towards the Detection of Prostate Cancer in Urine: a Critical Analysis. The J of Urology. 2012.
17. Alaoui-Jamali MA and Xu YJ. Proteomic technology for biomarker profiling in cancer: an update. J Zhejiang Univ Sci B. 2006; 7: 411-420.
18. Ong SE and Mann M. Mass spectrometry-based proteomics turns quantitative. Nat. Chem. Biol. 2005; 1: 252-262.
19. Hanash S. 2-D or not 2-D: is there a future for 2-D gels in proteomics? Insights from the York proteomics meeting. Proteomics 2001; 1: 635-637.
20. Sun W, Li F, Wu S, Wang X, Zheng D, Wang J and Gao Y. Human urine proteome analysis by three separation approaches. Proteomics 2005; 5: 4994-5001.
21. Wang L, Li F, Sun W, Wu S, Wang X, Zhang L, Zheng D, Wang J and Gao Y. Concanavalin A-captured glycoproteins in healthy human urine. Mol Cell Proteomics 2006; 5: 560-562.
22. Oh J, Pyo JH, Jo EH, Hwang SI, Kang SC, Jung JH, Park EK, Kim SY, Choi JY and Lim J. Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics 2004; 4: 3485-3497.
23. Theodorescu D and Mischak H. Mass spectrometry based proteomics in urine biomarker discovery. World J Urol. 2007; 25: 435-443.
24. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, Apweiler R, Haab BB, Simpson RJ, Eddes J S, Kapp EA, Moritz RL, Chan DW, Rai AJ, Admon A, Aebersold R, Eng J, Hancock WS, Hefta SA, Meyer H, Paik YK, Yoo JS, Ping P, Pounds J, Adkins J, Qian X, Wang R, Wasinger V, Wu CY, Zhao X, Zeng R, Archakov A, Tsugita A, Beer I, Pandey A, Pisano M, Andrews P, Tammen H, Speicher DW and Hanash SM. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly available database. Proteomics 2005; 5: 3226-3245.
25. Rehman I, Azzouzi AR, Catto JW, Allen S, Cross SS, Feeley K, Meuth M and Hamdy FC. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 2004; 64: 1238-1243.
26. Irmak S, Tilki D, Heukeshoven J, Oliveira-Ferrer L, Friedrich M, Huland H and Ergun S. Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics 2005; 5: 4296-4304.
27. Tantipaiboonwong P, Sinchaikul S, Sriyam S, Phncrakul S, Chen ST. Different techniques for urinary protein analysis of normal and lung cancer patients. Proteomics 2005; 5: 1140-1149
28. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS and Cramer DW. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res. 2006; 12: 432-441
29. Botezatu I, Serdyuk O, Potapova G, Shelepov V, Alechina R, Molyaka Y, Ananév V, Bazin I, Garin A, Narimanov M, Knysh V, Melkonyan H, Umansky S and Lichtenstein A. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem. 2000; 46: 1078-1084.
30. Nelson PS, Han D, Rochon Y, Corthals GL, Lin B, Monson A, Nguyen V, Franza BR, Plymate SR, Aebersold R and Hood L. Comprehensive analyses of prostate gene expression: convergence of expressed sequence tag databases, transcript profiling and proteomics. Electrophoresis 2000; 21: 1823-1831
31. Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA and Chinnaiyan AM. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J. Nat. Cancer Inst. 2004; 96: 834-843.
32. Downes MR, Byrne JC, Dunn MJ, Fitzpatrick JM, Watson RWG and Pennington SR. Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer: a review. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. 2006; 11(5): 406-416.
33. Wright ME, Han DK and Aebersold R. Mass spectrometry-based expression profiling of clinical prostate cancer. Mol Cell Proteomics 2005; 4: 545-554.
34. Serafini-Cessi F, Malagolini N and Cavallone D. Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis. 2003; 42: 658-676
35. Nagaraj N and Mann M. Quantitative analysis of the intra- and inter- individual variability of the normal urinary proteome. J of proteome Res. 2011; 10(2): 637-645.
36. Poon TC, Johnson PJ. Proteome analysis and its impact on the discovery of serological tumor markers. Clin Chim Acta. 2001; 313: 231-239.
37. Pisitkun T, Johnstone R and Knepper MA. Discovery of urinary biomarkers. Mol Cell Proteomics 2006; 5: 1760-1771.
38. Mehta AI, Ross S, Lowenthal MS, Fusaro V, Fishman DA, Petricoin EF. 3rd and Liotta LA. Biomarker amplification by serum carrier protein binding. Dis Markers. 2003; 19: 1-10.
39. Birchmeier W and Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim. Biophys. Acta, 1994; 1198: 11-26.
40. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet. 1993; 9: 317 - 321.
41. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HFM, Oosterhof GON, Debruyne FMJ, and Schalken JA. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994; 54: 3929-3933.
42. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, and Pignatelli M. Aberrant E-cadherin and a-catenin expression in prostate cancer: correlation with patient survival. Cancer Res. 1997; 57: 3189-3193.
43. Vleminkx K, Vakaet L, Mareel M, Fiers W, and Van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991; 66: 107-119.
44. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, and Isola JJ. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am. J. Clin. Pathol. 1996; 105: 394-402.
45. Bosman FT and Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol. 2003; 200(4): 423-428.
46. Jiang WG, Puntis MC and Hallett MB. Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. Br J Surg. 1994; 81(11): 1576-1590
47. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
48. Schwarzbauer JE and Desimone DW. Fibronectins, Their Fibrillogenesis, and In Vivo Functions. Cold Spring Harb Perspect Biol. 2011; 3: a005041.
49. Sottile J and Hocking DC. Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol Biol Cell 2002; 13: 3546-3559.
50. Weinberg R. The Biology of Cancer. Garland Science. ISBN 9780815340782. 2006
51. Goel HL, Li J, Kogan S and Languino LR. Integrins in prostate cancer progression. Endocr Relat Canc. 2008;15: 657-664.
52. Knudsen BS and Miranti CK. The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression. J Cell Biochem 2008; 99: 345-361.
53. Albrecht M, Renneberg H, Wennemuth G, Moschler O, Janssen M, Aumuller G and Konrad L. Fibronectin in human prostatic cells in vivo and in vitro: expression, distribution, and pathological significance. Histochem Cell Biol. 1999; 112: 51-61
54. Jia D, Entersz I Butler C and Foty RA. Fibronectin matrix-mediated cohesion suppresses invasion of prostate cancer cells. BMC Cancer 2012; 12: 94.
55. Nowak J. and Iovanna JL. TP53INP2 is the new guest at the table of self-eating. Autophagy 2009; 5(3): 383-384.
56. Nowak JC, Archange J, Tardivel-Lacombe P, et al. The TP53INP2 protein is required for autophagy in mammalian cells. Molecular Biol of the cell 2009; 20(3): 870-881.
57. Rubinsztein DC, DiFiglia M, Heintz N, Nixon RA, Qin ZH, Ravikumar B, Stefanis L, Tolkovsky A. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 2005; 1(1): 11-22.
58. Mirzayans R, Andrais B, Scott A, Murray D. New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: Implications for Cancer Therapy. J of Biomedicine and Biotechnology 2012; :170325
59. Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA (2010). MicroRNA expression variability in human cervical tissues. PLoS ONE 2010; 5(7): e11780.
60. Staub E, Gröne J, Mennerich D, Röpcke S, Klamann I, Hinzmann B, Castanos- Velez E, Mann B, Pilarsky C, Brümmendorf T, Weber B, Buhr HJ, Rosenthal A. A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer. Molecular Cancer 2006; 5: 37.
61. Schlomm T, Näkel E, Lübke A, Buness A, Chun FK, Steuber T, Graefen M, Simon R, Sauter G, Poustka A, Huland H, Erbersdobler A, Sültmann H, Hellwinkel OJ. Marked gene transcript level alterations occur early during radical prostatectomy. 2008; 53(2): 333-44.
62. Merchant K, Kumi-Diaka J, Rathinavelu A, Esiobu N, Zoeller R, Hartmann J and Johnson M. Molecular basis of the anti-cancer effects of genistein isoflavone in LNCaP prostate cancer cells. Functional Foods in Health and Disease 2011.
63. Moran-Jones K, Grindlay J, Jones M, Smith R, Norman JC. hnRNP A2 regulates alternative mRNA splicing of TP53INP2 to control invasive cell migration. Cancer Res. 2009; 69(24): 9219-9227.
64. Poustka A. Gene expression signature for the prognosis, diagnosis and therapy of prostate cancer and uses thereof. US Patent Application. 2007. US 20100261617A1.
65. Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC, Key CR. Prostate- specific antigen testing accuracy in community practice. BMC Fam Pract. 2002; 3: 19.
66. Martins ACP, Borelli-Bovo TJ, Reis RB, Paschoalin EL, Cologna AJ, Suaid HJ. Performance of PSA and of PSA Density in the Diagnosis of Prostate Carcinoma. Acta Cir. Bras. 2002; 17(3): 07-11.